Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Innovative Brain-Computer Interface for People With Spinal Cord Injury (INTENSE-BCI)

5 de junio de 2026 actualizado por: Erik Aarnoutse, PhD, UMC Utrecht

Innovative Neurotechnology For Society - Brain-Computer Interface

The goal of this clinical trial is to demonstrate control of digital devices through a brain implant in people with spinal cord injury. The main question it aims to answer is efficient, independent, BCI-based control over digital devices in settings of daily living of an individual with SCI. In this project an advanced generation fully implantable BCI system will be used, the Brain InterChange (BIC) from CorTec.

Participants will be implanted with an electrode grid on the surface of the brain and an amplifier/transmitter on the skull, under the skin. Participation includes visits of researchers for recording and training at home, 1-3 times per week for one year. Extension of participation after one year is possible. If successful, the participant will be able to use the BCI at home independently, without the presence of a researcher.

Descripción general del estudio

Descripción detallada

Spinal Cord Injury (SCI) results in motor impairments in body parts innervated by the spinal cord below the site of the lesion. In addition to loss of leg movements, individuals with high cervical SCI experience significant impairments in arm and hand function (tetraplegia), impacting their access to digital devices, with obvious consequences for their ability to communicate, participate in society and the workforce, autonomously manage their life, and benefit from the entertainment options digital devices offer these days. Current assistive technologies (AT) for control over digital devices, such as voice control, eye-tracking, and head- or mouth-controlled devices, are often unintuitive, slow, limited in functionality, aesthetically unattractive, and they often interfere with regular movement or speech. An effective Brain-Computer Interface (BCI) would enable individuals with SCI to use movement-related neural signals to directly control digital devices, taking away the disadvantages of current AT. This would dramatically improve their quality of life.

The Brain InterChange from CorTec is an active implantable medical device for measurement of neuronal activity and electrical stimulation of the human nervous system, comprising an internal and an external unit. The internal unit consists of a small high-density ECoG grid with 32 contacts placed subdurally and a connected implantable amplifier/transmitter device that is placed subcutaneously. The external unit comprises a headpiece, for power transmission to the internal unit, a communication unit, that receives the data transmitted from the internal unit and controls the power transmission, and a USB cable, that connects the communication unit to the computer that has software to process and translate the brain data to a means of digital device control for SCI patients with custom in-house software developed during this study.

The BCI system also allows to provide users with somatosensory feedback about their motor attempts (in addition to the visual feedback), by delivering electrocortical stimulation (ECS) to the somatosensory regions of the brain. As such, the aim is to generate a more natural relation between intent (movement attempt of a body part) and effect (sensation in the same body part), which is expected to lead to fast training and accurate BCI performance.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

1

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Utrecht
      • Utrecht, Utrecht, Países Bajos, 3584CX
        • Reclutamiento
        • University Medical Center Utrecht
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Nick F Ramsey, PhD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Clinical diagnosis of SCI at the cervical level C4 or higher (C1-C4)
  • Complete or incomplete tetraplegia (quadriplegia) or tetraparesis (quadriparesis), i.e., level A or B at the American Spinal Injury Association (ASIA) Impairment Scale
  • Meeting surgical safety criteria, including surgical clearance by the study physicians
  • Meeting (neuro)psychological evaluation criteria
  • Ability to communicate reliably, via speech or other means
  • Willingness and ability to provide informed consent.
  • Lives within reasonable distance from UMC Utrecht
  • Participant consents to the study and still wishes to participate at the time of the study.
  • Vision and hearing largely intact.
  • For candidates who are not currently receiving invasive ventilation, and who have current respiratory problems (e.g., at night), there should be a clear and confirmed desire to proceed with tracheostomy ventilation whenever that would become necessary.

Exclusion Criteria:

  • Having a spinal cord injury with a degenerative or progressive etiology.
  • Having evident swallowing problems.
  • Having a significant current or recent anxiety disorder or depression or cognitive impairment that would interfere with obtaining informed consent or fully participating in study activities.
  • Medical conditions contraindicating surgery of a chronically implanted device or that could interfere with study participation (for example active infections, unexplained fever, existing scalp lesions or skin breakdown, osteomyelitis, hepatitis, any autoimmune disease/disorder, epilepsy, skin disorders causing excessive skin sloughing or poor wound healing, cranioplasty, significant cardiovascular, metabolic, or renal impairments, chronic oral or intravenous use of steroids or immunosuppressive therapy, active cancer within the past year or requires chemotherapy, uncontrolled autonomic dysreflexia within the past 3 months, hydrocephalus with or without an implanted ventricular shunt or a medical contraindication to stop anti-coagulant medications during surgery, or a catabolic state, or strong and frequent spasms)
  • Presence of pre-surgical findings in anatomical, functional, and/or vascular neuroimaging that makes achieving implant locations too challenging or incompatible with desired risk levels.
  • Inability to undergo MRI for pre-implantation evaluation, for example due to the presence of implanted devices that are incompatible with MRI, which may include pacemakers, cardiac defibrillators, spinal cord or vagal nerve stimulators, deep brain stimulators, and cochlear implants or devices that deliver diaphragm pacing.
  • Anticipated need for MRI after implantation of the Brain InterChange system.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: ECoG (electrocorticography) sensing
Use implantable ECoG-based Brain Computer interface to control digital devices
Implant electrodes and amplifier/transmitter and use, through amplifier and decoding, for control of BCI
Otros nombres:
  • Brain Interchange

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Effectiveness of BCI Control: Accuracy
Periodo de tiempo: 1 year
Accuracy: >80% sensitivity (true positive rate) for 1-command control; 80% classification accuracy (distinguishing between multiple classes) for multi-command control; and 80% classification accuracy and the correlation between the intended and actual response for multi-command continuous control
1 year
Efficiency of BCI control: Speed
Periodo de tiempo: 1 year
number of accurate selections made per minute
1 year
Efficiency of BCI control: Subjective Workload - Visual Analogue Scale
Periodo de tiempo: 1 year
Subjective Workload: Visual Analogue Scale Continuous scale: Little to no effort (0) - Much effort (5). Lower numbers are better.
1 year
Efficiency of BCI control: Subjective Workload - National Aeronautics and Space Administration-Task Load Index
Periodo de tiempo: 1 year
Subjective Workload: National Aeronautics and Space Administration-Task Load Index Scale: 21 point Likert-type scale. Lower numbers are better.
1 year
User satisfaction Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)
Periodo de tiempo: 1 year

User Satisfaction: Quebec User Evaluation of Satisfaction with assistive Technology version 2.0.

Likert-type scale: Extremely dissatisfied - Dissatisfied - Slightly satisfied - Satisfied - Extremely satisfied. Extremely Satisfied is the best result.

1 year
user satisfaction Psychosocial impact of assistive devices scale (PIADS)
Periodo de tiempo: 1 year
User Satisfaction: Psychosocial impact of assistive devices scale. Likert-type scale -3, -2, -1, 0, 1, 2, 3. 3 is best result.
1 year
Stability of BCI performance: impedance
Periodo de tiempo: 1 year
Longitudinally follow the electrode impedance (in Ω), to assess their stability throughout the day and across the weeks and months after implantation.
1 year
Stability of BCI performance: signal dynamics
Periodo de tiempo: 1 year
Longitudinally follow the raw signal dynamics (in µV) of neural signals, to assess their stability throughout the day and across the weeks and months after implantation.
1 year
Stability of BCI performance: task-related modulation
Periodo de tiempo: 1 year
Longitudinally follow the task-related modulation in power (in µV), to assess their stability throughout the day and across the weeks and months after implantation.
1 year
Effects of somatosensory feedback on BCI Training and Performance: accuracy
Periodo de tiempo: 1 year
Compare BCI control accuracy (in %), including variability and improvement therein before and after applying somatosensory feedback through electrocortical stimulation of the somatosensory cortex
1 year
Effects of somatosensory feedback on BCI Training and Performance: neural signals
Periodo de tiempo: 1 year
Compare neural signal changes (in µV) in the sensorimotor areas before and after applying somatosensory feedback through electrocortical stimulation of the somatosensory cortex
1 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Assess device specifications for future, larger-scale, application of HD ECoG-BCIs
Periodo de tiempo: 1 year
qualitative description on device specifications and experimental parameters, such as the specific decoder settings, for future, larger scale, application of HD ECoG-BCIs
1 year
Validation of software for independent home-use of advanced BCIs
Periodo de tiempo: 1 year

Validation: Questionnaire to evaluate user satisfaction and ease of use of the home use software.

Likert-type scale: fully disagree - disagree - neither agree or disagree - agree - fully agree - not applicable. Fully agree is the best result.

1 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Nick F Ramsey, PhD, UMC Utrecht

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de agosto de 2026

Finalización primaria (Estimado)

1 de agosto de 2027

Finalización del estudio (Estimado)

1 de agosto de 2028

Fechas de registro del estudio

Enviado por primera vez

29 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

5 de junio de 2026

Publicado por primera vez (Actual)

11 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

11 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

selected datasets will be available through a public repository after publication of results

Marco de tiempo para compartir IPD

after first published results, no end date

Criterios de acceso compartido de IPD

Publicly available

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir